Skip to content

TO EVALUATE THE EFFICACY OF MUSTADI TAILA NASYA IN THE MANAGEMENT OF DUSHTA PRATISHYAYA

A RANDOMIZED OPEN LABEL CONTROLLED CLINICAL STUDY ON THE EFFICACY OF MUSTADI TAILA NASYA IN THE MANAGEMENT OF DUSHTA PRATISHYAYA - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/107272
Enrollment
30
Registered
2026-04-01
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J329- Chronic sinusitis, unspecified

Interventions

None listed

Sponsors

Dr Nisa M
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects aged between 18 to 40 years, irrespective of gender, occupation and socio-economic status. 2.Subjects presenting with Lakshanas of Dushta Pratishyaya like Nasasrava, Nasaavrodha, Gandha na vethi, Nishwasa, Ucchvasa, and Dourgandhya . 3.Signs and symptoms of chronic sinusitis. 4.Subjects willing to undergo trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1.Subjects with diagnosed cases of any systemic illness. 2.Subjects suffering from other systemic infectious disease. 3.Pregnant and lactating women. 4.Subjects suffering with Polyps, deviated nasal septum who require surgical intervention. 5.Subjects who are contraindicated for Nasya.

Design outcomes

Primary

MeasureTime frame
To clinically evaluate the efficacy of Mustadi Taila Nasya in the management of Dushta Pratishyaya with special reference to chronic sinusitis and compare with the efficacy of Lashuna Taila Nasya on the basis of Subjective and Objective parameters.Timepoint: Trial period 30 days.Assessment 0th day,8th day,15th day,and 22nd day.Follow up on 30th day

Secondary

MeasureTime frame
1.To conduct a detailed literary review of Dushta Pratishyaya with special reference to chronic sinusitis. 2.To conduct the analysis and standardization of Mustadi Taila. 3.To record any possible adverse drug reaction and adverse drug events. Timepoint: Trial period 30 days.Assessment 0th day,8th day,15th day,and 22nd day.Follow up on 30th day

Countries

India

Contacts

Public ContactDr Naveen B S

Sri Sri College of Ayurvedic Science And Research, Bengaluru

Navs009@gmail.com9844991405

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026